CytomX Reports Q4 2025 Earnings and Phase I Trial Data for Varseta-M
CytomX (CTMX) provided updates on its Phase I trial of Varseta-M, showing a confirmed overall response rate of 32% at the higher dose level. The drug demonstrated improved progression-free survival compared to earlier estimates and showed reduced adverse events with optimized dosing strategies.
